Brd. 2 Pharmacology and safety factors affecting use of flat (rather than weight-based) dosing of tesetaxel, an orally administered taxane. (Abstract #2510) R. P. Warrell, M. Beeram, E. Spindler, K. Papadopoulos, A. Patnaik, A. W. Tolcher
Brd. H3 Survival of advanced melanoma patients with normal LDH treated with oblimersen, temozolomide, and nabpaclitaxel. (Abstract #9080) A. C. Pavlick, P. Ott, J. Escalon, K. Madden, E. Yepes, J. Staha, S. Mendoza, A. Gandhi, H. Yee, L. Liebes